ClinicalTrials.gg
CompletedNCT07094815LLS-HYSUpdated Aug 6, 2025

Effectiveness of Laparoscopic Lateral Suspension With or Without Hysterectomy in Pelvic Organ Prolapse

An observational study in Pelvic Organ Prolapse (POP) and Uterine Prolapse, sponsored by Havva Betül Bacak. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-06.

Primary conditionUterine ProlapseRegistry: Pelvic Organ ProlapseReclassifiedWhy we changed it
Registry
Pelvic Organ Prolapse — the first condition term the registry derived for this study.
ClinicalTrials.gg
Uterine Prolapse
Why
  1. The study's listed conditions name Uterine Prolapse, a narrower term within Pelvic Organ Prolapse.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Havva Betül Bacak · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
87
Ages
40 Years to 80 Years
Sex
Female
01

Study summary

This study aims to compare the effectiveness of laparoscopic lateral suspension (LLS) with and without hysterectomy in the treatment of pelvic organ prolapse. Pelvic organ prolapse is a condition that affects many women and can significantly reduce quality of life. Laparoscopic lateral suspension is a minimally invasive surgical technique used to correct this condition. In some cases, the uterus is preserved, while in others, hysterectomy is performed at the same time.

The study retrospectively evaluates patients who underwent laparoscopic lateral suspension, either with or without hysterectomy, at SBÜ Gaziosmanpaşa Training and Research Hospital. Medical records were reviewed to collect information about surgery duration, anatomical success (measured by the POP-Q system), complication rates, blood loss, hospital stay, and recurrence rates.

The goal of this study is to determine whether performing a hysterectomy during laparoscopic lateral suspension has a significant effect on surgical outcomes. The findings may help guide surgical decision-making and improve treatment strategies for women with pelvic organ prolapse.

Read the detailed description

This retrospective cohort study was conducted at SBÜ Gaziosmanpaşa Training and Research Hospital to compare the outcomes of laparoscopic lateral suspension (LLS) with and without concomitant hysterectomy in women with pelvic organ prolapse (POP). POP is a prevalent condition that significantly affects quality of life, and LLS is increasingly performed as a minimally invasive approach that allows either uterine preservation or hysterectomy.

A total of 87 patients treated between 2021 and 2024 were analyzed: 43 underwent LLS with total laparoscopic hysterectomy, and 44 underwent uterus-preserving LLS. Preoperative, intraoperative, and postoperative data were collected from electronic medical records, operative reports, and follow-up documentation, with at least 12 months of follow-up. Outcome measures included POP-Q scores, operative time, blood loss, hospital stay, perioperative complications, recurrence, pelvic pain, and urinary incontinence.

The analysis showed that both groups achieved significant anatomical improvement, with no significant differences in recurrence, pelvic pain, or urinary incontinence. However, hysterectomy was associated with longer operative times, increased blood loss, and longer hospital stays. Vaginal length was better preserved in uterus-preserving procedures. No major intraoperative or postoperative complications occurred.

These findings indicate that adding hysterectomy to LLS increases surgical burden without conferring additional anatomical or functional benefit. Uterus-preserving LLS appears to be a safe and effective option in appropriately selected patients, supporting shared decision-making in pelvic reconstructive surgery.

02

Conditions studied

  • Pelvic Organ Prolapse (POP)
  • Uterine Prolapse

Browse trials for

Keywords

  • Laparoscopic Lateral Suspension
  • Uterus Preservation
  • Uterine Prolapse
  • Pelvic Organ Prolapse
  • Minimally Invasive Surgery
  • POP-Q System
  • Surgical Outcomes
  • Gynecologic Surgery
  • Pelvic Floor Disorders
03

In context

Uterine Prolapse Reclassified

111 studies on the registry are indexed under Uterine Prolapse; 18 are open to participants now.

This study's enrollment of 87 is below the median of 99 across 34 observational studies indexed under Uterine Prolapse.

Browse Uterine Prolapse studies →

Lead sponsor

Havva Betül Bacak is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Compared within Uterine Prolapse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pelvic Organ Prolapse. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Female patients aged 40 to 80 years who underwent laparoscopic lateral suspension (LLS) with or without concomitant total laparoscopic hysterectomy for the treatment of pelvic organ prolapse at SBÜ Gaziosmanpaşa Training and Research Hospital between 2021 and 2024. All patients had at least 12 months of postoperative follow-up, and data were collected retrospectively from medical records.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 40 to 80 years
  • Diagnosis of pelvic organ prolapse (POP) requiring surgical management
  • Underwent laparoscopic lateral suspension (LLS) with or without concomitant total laparoscopic hysterectomy
  • Minimum of 12 months postoperative follow-up available
  • Ability to provide for use of medical data in this retrospective study

Exclusion criteria

Exclusion Criteria:

  • History of connective tissue disorders
  • History of prior pelvic reconstructive surgery
  • Active pelvic infection or suspected at the time of surgery
  • Severe systemic disease that could significantly affect surgical outcomes
  • Incomplete medical records or missing follow-up data
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
87 participants (actual)
Patient registry
No

Groups and cohorts

  • LLS with Hysterectomy

    Patients who underwent laparoscopic lateral suspension combined with total laparoscopic hysterectomy.

  • Uterus-Preserving LLS

    Patients who underwent laparoscopic lateral suspension with uterine preservation.

06

What researchers measure

Primary outcomes

  1. Anatomical Success Based on POP-Q System

    Primary Outcome Title: Number of Participants Achieving Anatomical Success Based on POP-Q System Description: Anatomical success is defined as all assessed POP-Q points (Aa, Ba, C, D, Ap, Bp) being at or above -1 cm (no prolapse extending more than 1 cm below the hymen). POP-Q scale values: Negative values indicate the point is above the hymen (better anatomy), positive values indicate prolapse below the hymen (worse anatomy). Typical range: Aa, Ba, Ap, Bp = -3 to +3 cm; C and D vary according to total vaginal length (TVL). Time Frame: 12 months after surgery

    Time frame: 12 months after surgery

07

Study locations

1 site
  • University of Health Sciences, Gaziosmanpaşa Training and Research Hospital
    Istanbul, Istanbul 34255, Turkey (Türkiye)
08

References and documents

Publications

  • Kumbasar S, Salman S, Sogut O, K Gencer F, Bacak HB, Tezcan AD, Timur GY. Uterine-sparing laparoscopic lateral suspension in the treatment of pelvic organ prolapse. J Obstet Gynaecol Res. 2023 Jan;49(1):341-349. doi: 10.1111/jog.15459. Epub 2022 Oct 5. PubMed 36196844 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because this study is based on retrospective medical record review and no consent for data sharing was obtained from participants. All data are stored and analyzed internally according to institutional policies and ethical approvals.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Jun 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Jul 30, 2025
StartActual
May 28, 2025
Primary completionActual
Jun 28, 2025
CompletionActual
Jun 28, 2025
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07094815
Lead sponsor
Havva Betül Bacak
Responsible party
Havva Betül Bacak (M.D, Gaziosmanpasa Research and Education Hospital) — Sponsor-investigator
First posted
Jul 30, 2025
Start date
May 28, 2025
Primary completion
Jun 28, 2025
Completion
Jun 28, 2025
Last update
Aug 6, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion